A China licensing deal from Genfit and the collapse of Conatus provide the latest news from the closely watched Nash space, which nervously awaits the next wave of…
Abbvie’s bid for Allergan shows that the Botox franchise is impenetrable. The market agrees.
2019’s second mega-merger has emerged, and Vantage has crunched some EvaluatePharma data to help dissect the proposed deal.
Abbvie’s swoop on Allergan looks like a case of opportunism over innovation.
The developer of Keytruda is starting to look like a one-drug company; what must it do to avoid becoming the next Abbvie?
Novartis will need to boost Xiidra sales to justify the hefty price it has paid, but the Swiss company has form.
A flop in a small depression trial hits Vistagen Therapeutics, but the group insists that all is well ahead of its main event.
Payment of an overdue $120m Astrazeneca milestone, plus two other obligations, has been met through a loan facility with undisclosed terms.